Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SEMA3B Biologics Sequence Review Report 2026: Semaphorin-3B Similarity and Patent-Risk Signals
8 min read
SEMA3B Biologics Sequence Review Report 2026: Semaphorin-3B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3A Biologics Sequence Review Report 2026: Semaphorin-3A Similarity and Patent-Risk Signals
8 min read
SEMA3A Biologics Sequence Review Report 2026: Semaphorin-3A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARF2 Biologics Sequence Review Report 2026: Scavenger receptor class F member 2 Similarity and Patent-Risk Signals
8 min read
SCARF2 Biologics Sequence Review Report 2026: Scavenger receptor class F member 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP17 Biologics Sequence Review Report 2026: Matrix metalloproteinase-17 Similarity and Patent-Risk Signals
8 min read
MMP17 Biologics Sequence Review Report 2026: Matrix metalloproteinase-17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP24 Biologics Sequence Review Report 2026: Matrix metalloproteinase-24 Similarity and Patent-Risk Signals
8 min read
MMP24 Biologics Sequence Review Report 2026: Matrix metalloproteinase-24 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP24 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP9 Biologics Sequence Review Report 2026: Matrix metalloproteinase-9 Similarity and Patent-Risk Signals
8 min read
MMP9 Biologics Sequence Review Report 2026: Matrix metalloproteinase-9 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP16 Biologics Sequence Review Report 2026: Matrix metalloproteinase-16 Similarity and Patent-Risk Signals
8 min read
MMP16 Biologics Sequence Review Report 2026: Matrix metalloproteinase-16 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRP3 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 3 Similarity and Patent-Risk Signals
8 min read
LRP3 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of LRP3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRRC32 Biologics Sequence Review Report 2026: Transforming growth factor beta activator LRRC32 Similarity and Patent-Risk Signals
8 min read
LRRC32 Biologics Sequence Review Report 2026: Transforming growth factor beta activator LRRC32 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of LRRC32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP15 Biologics Sequence Review Report 2026: Matrix metalloproteinase-15 Similarity and Patent-Risk Signals
8 min read
MMP15 Biologics Sequence Review Report 2026: Matrix metalloproteinase-15 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP15 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRP12 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 12 Similarity and Patent-Risk Signals
8 min read
LRP12 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 12 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of LRP12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPR156 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 156 Similarity and Patent-Risk Signals
8 min read
GPR156 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 156 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR156 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →